1. Search Result
Search Result
Results for "

seizure

" in MedChemExpress (MCE) Product Catalog:

154

Inhibitors & Agonists

5

Peptides

21

Natural
Products

3

Recombinant Proteins

17

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-123671

    Neuropeptide Y Receptor Neurological Disease
    CYM2503 is a putative GalR2-positive allosteric modulator. CYM2503 increases the latency to first electrographic seizure and decreases the total time in seizure. CYM2503 also attenuates electroshock-induced seizures in mice. Galanin receptors type 1 (GalR1) and/or type 2 (GalR2) represent unique pharmacological targets for the research of seizures and epilepsy .
    CYM2503
  • HY-111177

    Ethylphenacemide; M 551

    Drug Metabolite Neurological Disease
    Pheneturide (Ethylphenacemide, M 551), a decarboxylation product of Phenobarbital, can be used to prevent psychomotor seizures .
    Pheneturide
  • HY-12503
    CFM-2
    1 Publications Verification

    iGluR Neurological Disease Cancer
    CFM-2 is a potent and selective non-competitive AMPAR antagonist . CFM-2 possesses anticonvulsant activity in various models of seizures .
    CFM-2
  • HY-B0495
    Lamotrigine
    5+ Cited Publications

    LTG; BW430C

    Sodium Channel Autophagy Neurological Disease Cancer
    Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na + channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy, focal seizure, et al .
    Lamotrigine
  • HY-131204

    Caspase Neurological Disease
    CZL80, a brain-penetrable caspase-1 inhibitor with an IC50 of 0.01 μM, could be used in the study of febrile seizures and later enhanced epileptogenic susceptibility .
    CZL80
  • HY-100922

    iGluR Neurological Disease
    N-Acetylglycyl-D-glutamic acid is a peptide with excitatory effect. N-Acetylglycyl-D-glutamic acid induces seizures in mice .
    N-Acetylglycyl-D-glutamic acid
  • HY-172531

    Dynamin Ras Neurological Disease
    Sulfonadyn-47 is a GTP-competitive dynamin I (dynI) inhibitor that targets the active site in the GTPase domain of dynamin I, with IC50 values of 3.5 μM against dynI, 27.3 μM in clathrin-mediated endocytosis (CME) assays, and 12.3 μM in synaptic vesicle endocytosis (SVE) assays. Sulfonadyn-47 increases seizure threshold. Sulfonadyn-47 can be used the study for the seizure[1].
    Sulfonadyn-47
  • HY-B0495A

    LTG hydrate; BW430C hydrate

    Sodium Channel Autophagy Neurological Disease Cancer
    Lamotrigine hydrate is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine hydrate selectively blocks voltage-gated Na + channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine hydrate can be used for the research of epilepsy, focal seizure, et al .
    Lamotrigine hydrate
  • HY-121595

    DPB

    Others Neurological Disease
    5,5-Diphenylbarbituric acid is an organic compound belonging to the derivatives of barbituric acid. 5,5-Diphenylbarbituric acid can be used for seizure study .
    5,5-Diphenylbarbituric acid
  • HY-W751152

    GABA Receptor Cancer
    α,β-Thujone is a component of the essential oils of some plants. α,β-Thujone causes cancers in male rats and induces seizures in the highest doses .
    α,β-Thujone
  • HY-153068

    Caspase Inflammation/Immunology
    CZL55 is a caspase-1 inhibitor with an IC50 value of 24 nM. CZL55 can be used for the research of febrile seizures (FS) .
    CZL55
  • HY-W013378

    Endogenous Metabolite Neurological Disease
    Carbamazepine 10,11-epoxide is an orally active metabolite of Carbamazepine (HY-B0246). Carbamazepine has anticonvulsant effect. Carbamazepine can be used for the research of seizures .
    Carbamazepine 10,11-epoxide
  • HY-111177R

    Ethylphenacemide (Standard); M 551 (Standard)

    Drug Metabolite Reference Standards Neurological Disease
    Pheneturide (Standard) is the analytical standard of Pheneturide. This product is intended for research and analytical applications. Pheneturide (Ethylphenacemide, M 551), a decarboxylation product of Phenobarbital, can be used to prevent psychomotor seizures .
    Pheneturide (Standard)
  • HY-130325

    NO Synthase Neurological Disease
    α-Guanidinoglutaric acid is a guanidino compound first found in cobaltinduced epileptogenic focus tissue in the cerebral cortex of cats. α-Guanidinoglutaric acid induces epileptic seizures in rats after intraventricular administration .
    α-Guanidinoglutaric acid
  • HY-129718

    Drug Metabolite Neurological Disease
    Nafimidone alcohol is the major metabolic of Nafimidone in plasma and urine. Nafimidone alcohol is promising for research of onset seizures .
    Nafimidone alcohol
  • HY-12503R

    iGluR Neurological Disease Cancer
    CFM-2 (Standard) is the analytical standard of CFM-2. This product is intended for research and analytical applications. CFM-2 is a potent and selective non-competitive AMPAR antagonist . CFM-2 possesses anticonvulsant activity in various models of seizures .
    CFM-2 (Standard)
  • HY-B0495S6

    LTG-13C2,15N2,d3; BW430C-13C2,15N2,d3

    Autophagy Sodium Channel Isotope-Labeled Compounds Neurological Disease Cancer
    Lamotrigine- 13C2, 15N2,d3 is 15N and deuterated labeled Lamotrigine (HY-B0495). Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na + channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy, focal seizure, et al .
    Lamotrigine-13C2,15N2,d3
  • HY-B1657

    Drug Intermediate Neurological Disease
    Fosphenytoin is a phosphate ester proagent developed as an alternative to intravenous phenytoin for acute intervention of seizures. Fosphenytoin has advantages including more convenient and rapid intravenous administration, availability for intramuscular injection, and low potential for adverse local reactions at injection sites .
    Fosphenytoin
  • HY-B0495R
    Lamotrigine (Standard)
    5+ Cited Publications

    LTG (Standard); BW430C (Standard)

    Reference Standards Sodium Channel Neurological Disease
    Lamotrigine (Standard) is the analytical standard of Lamotrigine. This product is intended for research and analytical applications. Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na + channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy, focal seizure, et al .
    Lamotrigine (Standard)
  • HY-118467

    CL11366

    Carbonic Anhydrase Neurological Disease Cancer
    Benzolamide (CL11366) is a potent carbonic anhydrase (CA) inhibitor, with Kis of 15 nM, 9 nM, 94 nM and 78 nM for hCA I, hCA II, EcoCAγ and VchCAγ, respectively. Benzolamide also inhibits CAS3, with a Ki of 54 nM. Benzolamide can be used for the research of glaucoma and seizures .
    Benzolamide
  • HY-W751152R

    Others Reference Standards Cancer
    α,β-Thujone (Standard) is the analytical standard of α,β-Thujone. This product is intended for research and analytical applications. α,β-Thujone is a component of the essential oils of some plants. α,β-Thujone causes cancers in male rats and induces seizures in the highest doses .
    α,β-Thujone (Standard)
  • HY-W013378R

    Reference Standards Endogenous Metabolite Neurological Disease
    Carbamazepine 10,11-epoxide (Standard) is the analytical standard of Carbamazepine 10,11-epoxide. This product is intended for research and analytical applications. Carbamazepine 10,11-epoxide is an orally active metabolite of Carbamazepine (HY-B0246). Carbamazepine has anticonvulsant effect. Carbamazepine can be used for the research of seizures .
    Carbamazepine 10,11-epoxide (Standard)
  • HY-B1730
    Phensuximide
    1 Publications Verification

    Others Neurological Disease Metabolic Disease
    Phensuximide is an orally active succinimide antiepileptic and anticonvulsant agent. Phensuximide inhibits cyclic AMP and cyclic GMP accumulation in depolarized brain tissue. Phensuximide can be used for the study of seizure and petit mal .
    Phensuximide
  • HY-118467R

    Carbonic Anhydrase Neurological Disease Cancer
    Benzolamide (Standard) is the analytical standard of Benzolamide. This product is intended for research and analytical applications. Benzolamide (CL11366) is a potent carbonic anhydrase (CA) inhibitor, with Kis of 15 nM, 9 nM, 94 nM and 78 nM for hCA I, hCA II, EcoCAγ and VchCAγ, respectively. Benzolamide also inhibits CAS3, with a Ki of 54 nM. Benzolamide can be used for the research of glaucoma and seizures .
    Benzolamide (Standard)
  • HY-118696

    GABA Receptor Neurological Disease
    MGAT2-IN-5 (Compound 17b) is a selective inhibitor for mouse GABA transit protection subsidity 2 (mGAT2) with an IC50 of 45 μM. MGAT2-IN-5 exhibits anticonvulsive efficacy in audiogenic seizure (AGS) susceptible frings mouse model with an ED50 of 20.4 mg/kg .
    MGAT2-IN-5
  • HY-106316

    GABA Receptor Neurological Disease
    CGS 20625 is a potent, selective and orally active partial agonist for the central benzodiazepine receptor. CGS 20625 inhibits [3H]-flunitrazepam binding to central benzodiazepine receptors with an IC50 of 1.3 nM. CGS 20625 can be used for the research of pentylenetetrazol-induced seizures .
    CGS 20625
  • HY-171182

    Endogenous Metabolite Neurological Disease
    D3017 is the main metabolite of D2624, which has oral bioactivity and anti-convulsant effects. D3017 ED50 value is 1.5 mg/kg in mice, and it can be used for research on severe generalized tonic-clonic seizures (grand mal) and complex partial epilepsy .
    D3017
  • HY-A0092

    3,5,5,-Trimethyloxazolidine-2,4-dione

    Calcium Channel Neurological Disease
    Trimethadione (3,5,5,-Trimethyloxazolidine-2,4-dione) is an oxazolidinedione anticonvulsant agent widely used against absences seizures. Trimethadione also is a T-type calcium channel blocker which has antihyperalgesic effects .
    Trimethadione
  • HY-148327

    Adenosine Kinase Cardiovascular Disease Neurological Disease Inflammation/Immunology
    AK-IN-1 (compound 4072-2732) is an adenosine kinase (AK) inhibitor that is competitive for adenosine (Ado) but not for ATP. AK-IN-1 inhibits 86%, 87% and 89% of AK activity at concentrations of 2, 4 and 10 µM, respectively. AK-IN-1 has good potential for research in many disease areas, including ischaemia, inflammation and seizures .
    AK-IN-1
  • HY-B1730R

    Cyclic GMP-AMP Synthase Reference Standards Neurological Disease Metabolic Disease
    Phensuximide (Standard) is the analytical standard of Phensuximide. This product is intended for research and analytical applications. Phensuximide is an orally active succinimide antiepileptic and anticonvulsant agent. Phensuximide inhibits cyclic AMP and cyclic GMP accumulation in depolarized brain tissue. Phensuximide can be used for the study of seizure and petit mal .
    Phensuximide (Standard)
  • HY-139382

    Cytochrome P450 Neurological Disease
    2-(Isopentylamino)naphthalene-1,4-dione (compound 3d), a Vitamin K (HY-B2172) analogue, shows protection in Pentylenetetrazole (PTZ)-induced seizure model. 2-(Isopentylamino)naphthalene-1,4-dione significantly increases ATP levels in zebrafish as well as HT-22 cells. 2-(Isopentylamino)naphthalene-1,4-dione shows excellent permeability into the brain .
    2-(Isopentylamino)naphthalene-1,4-dione
  • HY-108497

    Somatostatin Receptor Neurological Disease Cancer
    L-803087 is a potent and selective somatostatin sst4 receptor agonist with a Ki of 0.7 nM. L-803087 is >280-fold higher than other somatostatin receptors. L-803087 facilitates AMPA-mediated hippocampal synaptic responses in vitro and increases kainate-induced seizures in mice .
    L-803087
  • HY-108497A

    Somatostatin Receptor Neurological Disease Cancer
    L-803087 TFA is a potent and selective somatostatin sst4 receptor agonist with a Ki of 0.7 nM. L-803087 TFA is >280-fold more selective for sst4 receptor than other somatostatin receptors. L-803087 TFA facilitates AMPA-mediated hippocampal synaptic responses in vitro and increases kainate-induced seizures in mice .
    L-803087 TFA
  • HY-A0092R

    3,5,5,-Trimethyloxazolidine-2,4-dione (Standard)

    Reference Standards Calcium Channel Neurological Disease
    Trimethadione (Standard) is the analytical standard of Trimethadione. This product is intended for research and analytical applications. Trimethadione (3,5,5,-Trimethyloxazolidine-2,4-dione) is an oxazolidinedione anticonvulsant agent widely used against absences seizures. Trimethadione also is a T-type calcium channel blocker which has antihyperalgesic effects .
    Trimethadione (Standard)
  • HY-108327

    Potassium Channel Neurological Disease
    PF-05020182 is an orally active opener for Kv7 channel, that activates human Kv7.2/7.3, Kv7.4 and Kv7.3/7.5 with EC50 of 334, 625 and 588 nM, respectively. PF-05020182 exhibits anticonvulsant activity in rats corneal electric shock-induced tonic seizure (MES) models. PF-05020182 is blood-brain barrier (BBB) penetrable .
    PF-05020182
  • HY-172887

    Potassium Channel Neurological Disease
    Kv7.2/Kv7.3 activator-2 is a BBB-penetrable Kv7.2/7.3 activator (EC50: 0.25 μM). Kv7.2/Kv7.3 activator-2 has good photostability. Kv7.2/Kv7.3 activator-2 has potently antiepileptic effects in maximal electroshock (MES) and sc-pentylenetetrazol (sc-PTZ)-induced acute mice seizure models .
    Kv7.2/Kv7.3 activator-2
  • HY-12596

    Calcium Channel Sodium Channel Potassium Channel Neurological Disease
    JNJ-26489112, a CNS-active agent, exhibits broad-spectrum anticonvulsant activity in rodents against audiogenic, electrically-induced, and chemically-induced seizures. JNJ-26489112 inhibits voltage-gated Na + channels and N-type Ca 2+ channels, and is effective as a K + channel opener. JNJ-26489112 has very weak inhibition of CA-II (IC50=35 μM) and CA-I (18 μM) .
    JNJ-26489112
  • HY-N2522
    Carboxyatractyloside dipotassium
    2 Publications Verification

    Gummiferin dipotassium

    Mitochondrial Metabolism Calcium Channel Reactive Oxygen Species (ROS) Neurological Disease
    Carboxyatractyloside dipotassium is a diterpenoid. Carboxyatractyloside dipotassium can be isolated from plants of the genus Xanthium. Carboxyatractyloside dipotassium is an ADP/ATP carrier inhibitor, inhibiting mitochondrial ADP/ATP transport. Carboxyatractyloside dipotassium promotes ROS production, induces Ca 2+ release, and leads to mitochondrial dysfunction. Carboxyatractyloside dipotassium induces lethargy, weakness, and epileptic seizures in rats .
    Carboxyatractyloside dipotassium
  • HY-N1502
    Carboxyatractyloside tripotassium
    2 Publications Verification

    Gummiferin tripotassium

    Mitochondrial Metabolism Reactive Oxygen Species (ROS) Calcium Channel Neurological Disease
    Carboxyatractyloside tripotassium is a diterpenoid. Carboxyatractyloside tripotassium can be isolated from plants of the genus Xanthium. Carboxyatractyloside tripotassium is an ADP/ATP carrier inhibitor, inhibiting mitochondrial ADP/ATP transport. Carboxyatractyloside tripotassium promotes ROS production, induces Ca 2+ release, and leads to mitochondrial dysfunction. Carboxyatractyloside tripotassium induces lethargy, weakness, and epileptic seizures in rats .
    Carboxyatractyloside tripotassium
  • HY-123934

    P-glycoprotein Neurological Disease
    VU6007477 is a brain-penetrant, selective M1 positive allosteric modulator (PAM) with an EC50 value of 230 nM. VU6007477 is also a human P-glycoprotein (P-gp) substrate with moderate permeability. VU6007477 displays improved central nervous system (CNS) penetration over the hydroxylated congeners. VU6007477 a pyranyl amide derivative, which is promising for research of robust cholinergic seizure activity .
    VU6007477
  • HY-100840

    (S)-4-Carboxy-3-hydroxyphenylglycine

    mGluR Neurological Disease
    (S)-4C3HPG ((S)-4-Carboxy-3-hydroxyphenylglycine) is an antagonist of metabotropic glutamate receptor 1a (mGluR 1a) and an agonist of GluR2. (S)-4C3HPG has the anticonvulsant activity and protects against audiogenic seizures in DBA/2 mice .
    (S)-4C3HPG
  • HY-103181

    CPA; UK-80882

    Adenosine Receptor Apoptosis Cardiovascular Disease Neurological Disease Cancer
    N6-Cyclopentyladenosine (CPA) is a selective Adenosine A1 receptor agonist, with Ki values of 2.3 nM, 790 nM and 43 nM for human A1, A2A and A3 receptors, respectively. N6-cyclopentyladenosine increases Apoptosis. N6-Cyclopentyladenosine has antitumor activity against leukemia. N6-cyclopentyladenosine improves 5-fluorouracil (HY-90006)-induced hematopoietic damage, regulates sleep, and delays Aminophylline-induced clonic epileptic seizures .
    N6-Cyclopentyladenosine
  • HY-10049

    Neurokinin Receptor Neurological Disease Inflammation/Immunology
    CP 122721 is an orally active NK1 receptor antagonist. CP 122721 attenuates cisplatin-induced vomiting in ferrets (ID50: 0.08 mg/kg). CP 122721 inhibits kainate (KA)-induced seizure activity and CA1 neuronal cell death in rats. CP 122721 is useful in the study of depression, asthma, and irritable bowel syndrome (IBS) .
    CP 122721
  • HY-W010155

    Indole-3-ethanol

    Endogenous Metabolite Apoptosis Caspase Bacterial Infection Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    Tryptophol is an aromatic alcohol and secondary metabolite produced by microorganisms. Tryptophol induces apoptosis and cleavage of caspase-8. Tryptophol inhibits Cunninghamella blakesleeana biofilm. Tryptophol has anti-phage infection, biofilm formation regulation, anti-inflammatory, hemolytic, sleep induction, temperature change, seizure susceptibility and immune regulation activities. Tryptophol is used in the research of African trypanosomiasis, sleep disorders, epilepsy .
    Tryptophol
  • HY-Y0378

    (R)-Leucine

    Endogenous Metabolite Neurological Disease
    D-Leucine is a more potent anti-seizure agent than L-leucine. D-leucine potently terminates seizures even after the onset of seizure activity. D-leucine, but not L-leucine, reduces long-term potentiation but had no effect on basal synaptic transmission in vitro .
    D-Leucine
  • HY-B0300
    Penicillamine
    2 Publications Verification

    D-(-)-Penicillamine

    Cuproptosis Drug Metabolite Inflammation/Immunology Cancer
    Penicillamine (D-(-)-Penicillamine) is a penicillin metabolic degradation product, can be used as a heavy metal chelator. Penicillamine reduces free copper and reduces oxidative stress. Penicillamine has effect of seizures through nitric oxide/NMDA pathways. Penicillamine is a potential immune modulator. Penicillamine can be used for the research of Wilson disease, rheumatoid arthritis, and cystinuria .
    Penicillamine
  • HY-100839

    D,L-(tetrazol-5-yl)glycine; LY 285265

    iGluR Neurological Disease
    (RS)-(Tetrazol-5-yl)glycine (D,L-(tetrazol-5-yl)glycine) is a highly potent and selective N-methyl-D-aspartate (NMDA) receptor agonist . (RS)-(Tetrazol-5-yl)glycine has EC50s of 99 nM, 1.7 μM for GluN1/GluN2D and GluN1/GluN2A, respectively . (RS)-(Tetrazol-5-yl)glycine induces seizure responses and Fos in mice .
    (RS)-(Tetrazol-5-yl)glycine
  • HY-B0124A

    AD 810 sodium; CI 912 sodium

    Carbonic Anhydrase Apoptosis Cardiovascular Disease Neurological Disease
    Zonisamide (AD 810) sodium is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide sodium exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide sodium also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide sodium can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .
    Zonisamide sodium
  • HY-B0124

    AD 810; CI 912

    Carbonic Anhydrase Apoptosis Neurological Disease
    Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .
    Zonisamide
  • HY-N2522R

    Gummiferin dipotassium (Standard)

    Reference Standards Mitochondrial Metabolism Calcium Channel Reactive Oxygen Species (ROS) Neurological Disease
    Carboxyatractyloside (dipotassium) (Standard) is the analytical standard of Carboxyatractyloside dipotassium (HY-N2522). This product is intended for research and analytical applications. Carboxyatractyloside dipotassium is a diterpenoid. Carboxyatractyloside dipotassium can be isolated from plants of the genus Xanthium. Carboxyatractyloside dipotassium is an ADP/ATP carrier inhibitor, inhibiting mitochondrial ADP/ATP transport. Carboxyatractyloside dipotassium promotes ROS production, induces Ca 2+ release, and leads to mitochondrial dysfunction. Carboxyatractyloside dipotassium induces lethargy, weakness, and epileptic seizures in rats .
    Carboxyatractyloside dipotassium (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: